HUM

Humana Inc.

Healthcare
US companies in Healthcare (47)
NYSE · USD
Mkt cap $49.8bn

$414.85

as of 27 Oct 2026, 9% below its 52-week high

Screens as less well placed to keep growing its dividend, though its cut-risk signals are low. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield: 0.64%Last 12 months of regular payments at today's price
Earnings cover: 3.0×Pays 34% of earnings
Cash cover: NegativeNegative free cash flow
5y dividend growth: +7.2% a yearLast cut in FY2016
Next ex-dividend date: Declared30 Oct 2026Quarterly dividend of $0.89

Compared with US companies in Healthcare (47)

Trailing yield is lower than 29 of the 46 other US companies in Healthcare.
5y dividend growth (as paid) is higher than 21 of the 38 other US companies in Healthcare with a 5y growth figure.

Quality

Low

Capacity to keep growing the dividend

Risk

Low

Signals of dividend-cut pressure

Trim

Moderate

How extended the valuation looks

Why Quality is 42

HUM against US companies in Healthcare (47)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of HUM’s past readings.

P/E37.4×P100, poor for this measure
Yield0.89%P76, good for this measure
Net debt / EBITDA2.37P92, poor for this measure
DGR 5y+6.0%P3, poor for this measure
ROIC4.4%P19, poor for this measure

Open valuation history

Forecast your income with the HUM dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.